Diabetes drug could hold key for Parkinson's patients 

20/05/2013 00:00 

A drug used to treat patients with diabetes could offer fresh hope to those affected by the debilitating symptoms of Parkinson’s disease, according to research led by the National Hospital for Neurology and Neurosurgery and UCL Institute of Neurology.

Dr Thomas Foltynie

Dr Thomas Foltynie


Parkinson’s Disease (PD), a degenerative disorder of the nervous system, affects at least one in 800 people, with an average age of onset of around 65–70 years.

Early in the course of the disease, the most obvious symptoms are movement-related; these include shaking, rigidity and difficulty with walking and gait. Later, thinking and behavioural problems may arise, with dementia commonly occurring in the advanced stages of the disease, whereas depression is the most common psychiatric symptom. Other symptoms include sensory, sleep and emotional problems.

In this month’s issue of the Journal of Clinical Investigation, Dr Thomas Foltynie and colleagues at the NHNN report the findings of an investigation into the use of a drug approved for diabetes care, Exenatide, in PD patients.

The results are encouraging.

PD patients on the trial were divided into two groups: 20 patients received Exenatide injections for 12 months, while the other group of 24 patients served as controls. Due to high manufacturing costs, the control group did not receive placebo injections and the patients were aware of their group assignment.

The researchers observed that Exenatide was well tolerated. After one year of treatment patients receiving Exenatide displayed improved cognitive ability and motor skills, while control patients declined.

Though this trial cannot rule out a placebo effect, the study suggests that Exenatide may improved motor function in PD patients and provides a strong rationale for conducting a larger, blinded study to determine the effectiveness of Exenatide in PD. This study was funded by Cure Parkinson's Trust.

Patient Arthur Lindley, 63, said it was a ‘valuable trial’ which showed the drug has promise. Using the drug meant he had been able to go on an alpine holiday with his wife.

Patient Arthur Lindley

Patient Arthur Lindley


“Having Parkinson’s made everything I used to do rather more difficult, from just walking about the house and eating a meal, to standing and talking to people.

“My own personal conclusion is that, at the very least it stopped any further deterioration in my condition. For four months afterwards I certainly did not get any worse and my wife and GP felt that I had improved.”

Dr Foltynie, consultant neurologist and senior lecturer, said: "This is encouraging news for patients with Parkinson's. We have seen a definite effect in patients that have been exposed to this drug for 12 months. However, whether this is placebo or an active effect of a biological medication we need to do further research to ascertain."

Tom Isaacs, Co-founder and President, The Cure Parkinson’s Trust, said:  “People with Parkinson’s guide the work of The Cure Parkinson’s Trust, informing research decisions and helping to prioritise areas of research, and this pivotal study was no exception. Perhaps most excitingly, the  accompanying editorial in the journal cites that these results  'speak in favour of a disease-modifying effect' ; the Holy Grail in a condition where existing treatments only provide temporary relief from symptoms. In a disease area where there is little innovation, it is so exciting to see new research avenues open up, as through this approach we really will move ever closer to a cure or cures.”  

The Cure Parkinson’s Trust is dedicated to finding a cure for Parkinson’s.  The charity funds and facilitates research investing in potential new therapies to halt or reverse the disease process.  www.cureparkinsons.org.uk registered charity number 1111816.

 

 Latest news

 Contact details

Communications unit
2nd floor central
250 Euston Road
London NW1 2PG

Media enquiries

Switchboard: 020 3456 7890
Media enquiries: 020 3447 7542 / 020 3447 9506
Email: uclh.media@nhs.net

Out of hours
The normal working hours for the Communications Unit are Monday to Friday 9am – 5pm. The only media enquiries that will be answered outside of these working hours are urgent enquiries and those relating to major incidents. To access the out-of-hours service call switchboard on 0845 155 5000.

Share this story